Author: Dr. Jia Li (Lily) Liu, Internal Medicine PGY-2, McGill UniversityExpert Reviewer: Dr. Gizelle Popradi, MD, Assistant Professor, Department of Medicine, Division of Hematology, McGill UniversityAfter completion of this self-assessment module, the learner will be able to:Understand how to diagnose Chronic Lymphocytic Leukemia (CLL). ...
In this video we will:1.Discuss the evidence from clinical trials for IVIG and SCIG for patients with hematologic malignancies and secondary hypogammaglobulinemia2.Estimate the cost of 1 year of IVIG or SCIG for the healthcare system3.Understand the evidence gap to be addressed by the RATIONAL-PT and...
Author: Julia Pennell MSc, MD, PGY2 Memorial UniversityExpert reviewer: Dr. Brian Harnett MD FRCPC, Clinical Assistant Professor, Memorial UniversityAccreditation: This activity is an Accredited Group Learning Activity (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons...
Speaker: Dr. Alissa Visram, Hematologist, The Ottawa Hospital. Assistant ProfessorLearning ObjectivesReview practise changing updates in myeloma over the last year Discuss how updates apply within the Canadian context Review therapies that are on the horizon in CanadaAccreditation: This activity is an Accredited Group Learning Activity (Section 1)...
Author: Dr. Jia Li (Lily) Liu, Internal Medicine PGY-2, McGill University Reviewer: Dr. Kelly Davison, MD, PhD, Assistant Professor, Department of Medicine, McGill UniversityAfter completion of this self-assessment module, the learner will be able to: 1. Describe the staging system for Hodgkin Lymphoma. 2. Describe favourable versus unfavourable...
Speaker: Christopher Patriquin MD MSc FRCPC Hematology & Apheresis Medicine, University Health Network Assistant Professor of Medicine, University of TorontoLearning ObjectivesReview the differential diagnosis of hemolytic anemias Discuss the recognition, diagnosis, and general management of paroxysmal nocturnal hemoglobinuria (PNH) Understand the pathophysiology, risk, and treatment of...
Answer and track your responses before watching the video.Q1: Can cardiotoxicity with BTK inhibitors be predicted? a. Yes to some extent, as underlying cardiac risks such as hypertension appear to precede the onset of cardiac arrhythmias. However, not all patients with hypertension develop cardiotoxicity and likewise,...
Author: Dr. Farid Azadian, University of OttawaReviewer: Dr. Kevin Imrie, Odette Cancer Centre (Sunnybrook Hospital)Learning ObjectivesAt the end of the self-assessment module, participants will be able to:Describe the treatment options for ALCL Describe the mechanism of action of Brentuximab vedotin Explain the efficacy and...
Authors: Dr. Thomas Kiebalo, Dr. Danyal Ladha, University of Toronto Reviewer: Dr. Hassan Sibai, Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer CentreLearning objectives At the end of this self-assessment module, participants will be...
Speaker: Mark Crowther, MD MSc FRCPC FRSC Chair, Department of Medicine Leo Pharma Chair in Thromboembolism Research McMaster UniversityLearning Objectives:Identify common issues in the management of ITP. Distinguish between those patients who do, and do not, require therapy. Appraise evidence for novel therapies in this area.Answer and...